Efficacy and Safety of Tirofiban in High‐Risk Patients With Non‐ST‐Segment Elevation Acute Coronary Syndromes

Objective To evaluate the safety and efficacy of tirofiban in high risk patients with non‐ST‐segment elevation acute coronary syndromes (NSTE‐ACS) after percutaneous coronary intervention (PCI). Methods A total of 240 patients were randomized to either a tirofiban group or a control group. Results Compared with the control group, the platelet aggregation rate in the tirofiban group was lower ( P < 0.01); the plasma levels of CK‐MB and troponin I, cardiac form (cTnI) were lower ( P < 0.05); ECG improved significantly ( P < 0.05); the incidence of major adverse cardiac events (MACE) was lower ( P < 0.05); and there was no difference in bleeding complications between the 2 groups ( P = 0.1). Conclusions The administration of tirofiban in high risk patients with NSTE‐ACS after PCI is safe and effective. Copyright © 2009 Wiley Periodicals, Inc.